JP2013528655A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528655A5
JP2013528655A5 JP2013515492A JP2013515492A JP2013528655A5 JP 2013528655 A5 JP2013528655 A5 JP 2013528655A5 JP 2013515492 A JP2013515492 A JP 2013515492A JP 2013515492 A JP2013515492 A JP 2013515492A JP 2013528655 A5 JP2013528655 A5 JP 2013528655A5
Authority
JP
Japan
Prior art keywords
compound according
compound
xanthine oxidase
oxidase inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528655A (ja
JP5551310B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040585 external-priority patent/WO2011159839A2/en
Publication of JP2013528655A publication Critical patent/JP2013528655A/ja
Publication of JP2013528655A5 publication Critical patent/JP2013528655A5/ja
Application granted granted Critical
Publication of JP5551310B2 publication Critical patent/JP5551310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515492A 2010-06-16 2011-06-15 チオ酢酸化合物、組成物、および、その使用方法 Active JP5551310B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35549110P 2010-06-16 2010-06-16
US61/355,491 2010-06-16
PCT/US2011/040585 WO2011159839A2 (en) 2010-06-16 2011-06-15 Thioacetate compounds, compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014105611A Division JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法

Publications (3)

Publication Number Publication Date
JP2013528655A JP2013528655A (ja) 2013-07-11
JP2013528655A5 true JP2013528655A5 (OSRAM) 2014-05-15
JP5551310B2 JP5551310B2 (ja) 2014-07-16

Family

ID=45348850

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013515492A Active JP5551310B2 (ja) 2010-06-16 2011-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2014105611A Active JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法
JP2015120633A Active JP6112318B2 (ja) 2010-06-16 2015-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2017035549A Active JP6364515B2 (ja) 2010-06-16 2017-02-27 チオ酢酸化合物、組成物、および、その使用方法
JP2018123691A Pending JP2018168174A (ja) 2010-06-16 2018-06-28 チオ酢酸化合物、組成物、および、その使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014105611A Active JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法
JP2015120633A Active JP6112318B2 (ja) 2010-06-16 2015-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2017035549A Active JP6364515B2 (ja) 2010-06-16 2017-02-27 チオ酢酸化合物、組成物、および、その使用方法
JP2018123691A Pending JP2018168174A (ja) 2010-06-16 2018-06-28 チオ酢酸化合物、組成物、および、その使用方法

Country Status (41)

Country Link
US (5) US10266493B2 (OSRAM)
EP (5) EP2975025B1 (OSRAM)
JP (5) JP5551310B2 (OSRAM)
KR (2) KR101608604B1 (OSRAM)
CN (2) CN103068801B (OSRAM)
AR (1) AR081930A1 (OSRAM)
AU (1) AU2011268360B2 (OSRAM)
BR (1) BR112012032028B1 (OSRAM)
CA (1) CA2802535C (OSRAM)
CL (1) CL2012003546A1 (OSRAM)
CO (1) CO6640311A2 (OSRAM)
CR (1) CR20120649A (OSRAM)
CU (1) CU24126B1 (OSRAM)
CY (1) CY1120337T1 (OSRAM)
DK (3) DK2585437T3 (OSRAM)
DO (1) DOP2012000314A (OSRAM)
EA (1) EA022933B1 (OSRAM)
EC (1) ECSP12012353A (OSRAM)
ES (3) ES2459146T3 (OSRAM)
GT (1) GT201200339A (OSRAM)
HN (1) HN2012002664A (OSRAM)
HR (3) HRP20140391T1 (OSRAM)
HU (2) HUE025962T2 (OSRAM)
IL (2) IL223435A (OSRAM)
LT (1) LT2975025T (OSRAM)
ME (2) ME02302B (OSRAM)
MX (2) MX2012014863A (OSRAM)
MY (1) MY153039A (OSRAM)
PE (1) PE20131047A1 (OSRAM)
PH (1) PH12012502460A1 (OSRAM)
PL (3) PL2712861T3 (OSRAM)
PT (3) PT2712861E (OSRAM)
RS (3) RS57363B1 (OSRAM)
SG (2) SG186298A1 (OSRAM)
SI (3) SI2585437T1 (OSRAM)
SM (3) SMT201800304T1 (OSRAM)
TR (1) TR201808344T4 (OSRAM)
TW (2) TWI501949B (OSRAM)
UA (1) UA107115C2 (OSRAM)
WO (1) WO2011159839A2 (OSRAM)
ZA (1) ZA201209574B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802692C (en) 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN106963761A (zh) 2011-11-03 2017-07-21 阿迪亚生命科学公司 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
AR093468A1 (es) * 2012-11-14 2015-06-10 Teijin Pharma Ltd Derivados de piridina
PL2998296T3 (pl) * 2013-05-13 2018-12-31 Shanghai Hengrui Pharmaceutical Co. Ltd. Pochodna kwasu cykloalkilowego, sposób jej otrzymywania i jej zastosowanie farmaceutyczne
PL3013796T3 (pl) 2013-06-27 2020-06-15 Lg Chem, Ltd. Pochodne biarylowe jako agoniści gpr120
PL3144306T3 (pl) * 2014-05-13 2018-04-30 Teijin Pharma Limited Pochodna pirazyny
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技(上海)有限公司 羧酸化合物及其制备方法和用途
PH12017501029B1 (en) * 2014-12-24 2022-04-27 Lg Chemical Ltd Biaryl derivative as gpr120 agonist
CA2971125C (en) * 2014-12-29 2024-05-21 Nippon Chemiphar Co., Ltd. Urat1 inhibitor
CN108026043A (zh) * 2015-08-14 2018-05-11 广东东阳光药业有限公司 一种萘环化合物的晶型
CN105418495B (zh) * 2015-11-25 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 一种硫醚的制备方法
CA3007783C (en) * 2015-12-07 2021-06-08 Hinova Pharmaceuticals Inc. Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
CN108699027B (zh) * 2015-12-28 2021-08-06 重庆复创医药研究有限公司 吲嗪类衍生物、组合物及使用方法
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
JP6971997B2 (ja) * 2016-02-15 2021-11-24 アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・(インセルム) 個体における尿中シュウ酸塩濃度を低下させるための、スチリペントール及びその誘導体の使用
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
JP7406990B2 (ja) 2016-11-11 2023-12-28 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト血漿様培地
CN106748987B (zh) * 2016-11-18 2019-05-31 昆药集团股份有限公司 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型
AU2017374992A1 (en) 2016-12-16 2019-06-20 Basf Se Pesticidal compounds
CN106883169A (zh) * 2017-04-01 2017-06-23 浙江永宁药业股份有限公司 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用
WO2018202039A1 (zh) * 2017-05-03 2018-11-08 成都海创药业有限公司 杂环化合物及其制备方法
AU2018345221A1 (en) * 2017-10-04 2020-05-07 Japan Tobacco Inc. Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
CN107955029B (zh) * 2017-12-07 2020-08-11 成都美域高制药有限公司 一种雷西纳德的制备方法
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN108069940B (zh) * 2017-12-20 2021-04-30 广东赛烽医药科技有限公司 硫代乙酸化合物、组合物及其应用
CN108440397B (zh) * 2018-03-06 2020-06-05 南方医科大学 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用
WO2019183835A1 (en) 2018-03-28 2019-10-03 Inventisbio Shanghai Ltd. Novel salt forms of urat-1 inhibitors
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
CA3145997A1 (en) 2019-07-16 2021-01-21 Astrazeneca Ab Dose dumping resistant pharmaceutical compositions comrising verinurad
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
CN114621136B (zh) * 2020-12-09 2023-11-07 江苏正大清江制药有限公司 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
US20240158378A1 (en) * 2021-03-01 2024-05-16 Orion Corporation Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor
AR124985A1 (es) * 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
CN113979931B (zh) * 2021-10-08 2023-06-13 南方医科大学 一种吡啶3-胺衍生物及其制备方法和应用
CN114214361A (zh) * 2022-01-07 2022-03-22 中国农业科学院兰州兽医研究所 一种urat1人源化小鼠模型的构建方法及其应用
WO2025060752A1 (zh) * 2023-09-19 2025-03-27 湘北威尔曼制药股份有限公司 一种硫醚衍生物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE642046A (OSRAM) * 1963-01-03
ES475100A1 (es) * 1977-11-21 1979-12-01 Hoechst Ag Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
SG86971A1 (en) 1990-11-30 2002-03-19 Teijin Ltd 2-arylthiazole derivatives and pharmaceutical composition thereof
JPH06234732A (ja) * 1992-09-10 1994-08-23 Banyu Pharmaceut Co Ltd 置換アセトアミド誘導体
US5405873A (en) 1992-09-10 1995-04-11 Banyu Pharmaceutical Co., Ltd. Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
BR0007663A (pt) * 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2135608B8 (en) 2004-08-25 2012-03-21 Ardea Biosciences, Inc. S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
US20060287319A1 (en) 2005-06-15 2006-12-21 Shibo Jiang Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
SI2133332T1 (sl) * 2007-04-11 2014-02-28 Kissei Pharmaceutical Co., Ltd. (aza)indolinski derivat in njegova uporaba v medicinske namene
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク. 新規化合物、組成物、及び使用方法
AU2009289646B2 (en) 2008-09-04 2012-07-05 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
WO2010135530A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
US20110082120A1 (en) 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CA2802692C (en) 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
CN106963761A (zh) * 2011-11-03 2017-07-21 阿迪亚生命科学公司 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物

Similar Documents

Publication Publication Date Title
JP2013528655A5 (OSRAM)
HRP20140391T1 (hr) Spojevi i pripravci tioacetata, te postupci uporabe
JP2012184234A5 (OSRAM)
JP2014532726A5 (OSRAM)
JP2017524704A5 (OSRAM)
JP2014532647A5 (OSRAM)
RU2018120242A (ru) Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
JP2013528650A5 (OSRAM)
JP2014012726A5 (OSRAM)
JP2017528503A5 (OSRAM)
JP2015508749A5 (OSRAM)
JP2013087119A5 (OSRAM)
JP2015057436A5 (OSRAM)
JP2016540749A5 (OSRAM)
JP2014532760A5 (OSRAM)
NZ709407A (en) Azole benzene derivative
JP2016520133A5 (OSRAM)
JP2015521156A5 (OSRAM)
CN115315423A (zh) 取代芳基类化合物
JP2008513510A5 (OSRAM)
JP2017509611A5 (OSRAM)
RU2014115733A (ru) Новая соль и медицинское применение
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
WO2006053161A8 (en) Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
JP2011527678A5 (OSRAM)